Subscribe
istock-497807150_erhui1979-1
erhui1979 / iStockphoto.com
30 January 2018Biotechnology

Cambridge University signs partnership to address innovation challenges

The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Mixed views on Broad’s fate after EPO revokes CRISPR patent
18 January 2018   Commentators have offered differing opinions on the impact of yesterday’s decision by the European Patent Office to revoke a CRISPR/Cas9 patent owned by the Broad Institute of Harvard and MIT.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Europe
Mixed views on Broad’s fate after EPO revokes CRISPR patent
18 January 2018   Commentators have offered differing opinions on the impact of yesterday’s decision by the European Patent Office to revoke a CRISPR/Cas9 patent owned by the Broad Institute of Harvard and MIT.

More on this story

Europe
Mixed views on Broad’s fate after EPO revokes CRISPR patent
18 January 2018   Commentators have offered differing opinions on the impact of yesterday’s decision by the European Patent Office to revoke a CRISPR/Cas9 patent owned by the Broad Institute of Harvard and MIT.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Explainer: ARIPO’s role in Plant Variety Protection